C ountry-or region-specific differences in outcomes are frequently observed in multinational clinical trials (1) (2) (3) and may or may not be indicative of true differences in drug response (4) . Geographies may vary with respect to genetics (4, 5) ; nongenetic racial characteristics (5, 6) ; medical practice, training, or infrastructure patterns that may influence outcomes despite general adherence to a clinical trial protocol (4) ; and other factors. In the planning and conduct of multinational clinical trials, the potential impact of geographic differences in outcomes is among many important factors that needs to be considered, but often is not taken into account (4).
The TOPCAT (Treatment of Preserved Cardiac
Function Heart Failure With an Aldosterone Antagonist Trial) (7, 8) was a large-scale, multinational National Heart, Lung, and Blood Institute (NHLBI)- with the NHLBI, and published data from the entire TOPCAT cohort (8, 11) . Interval enrollment data were the most recent figures available at the various reviews or from more extensive "data freeze" analyses performed within 2 months of the meetings.
STATISTICAL
METHODOLOGY. Analyses were as described for the TOPCAT trial (7, 8, 11 ) using an unadjusted model. Additional analyses were conducted using chi-square/contingency table tests with a Bonferroni correction. In addition to monthly safety monitoring that was focused on the class-adverse effects of mineralocorticoid receptor antagonists (MRAs) or MRAs in combination with other renin-angiotensin system inhibitors (hyperkalemia, renal function, gynecomastia in each blinded treatment arm), at its scheduled meetings, the DSMB monitored overall enrollment, the aggregate (both treatment groups combined) event rate, and country-specific data.
TOPCAT TRIAL
Throughout the trial, the DSMB elected not to disclose the observed aggregate event rate to the Executive/Steering Committee, but to report to them any important departure from the pre-trial assumption expected rate that might affect statistical power.
The interim analysis plan included a DSMB review of unblinded primary outcome data by treatment arm at 33%, 50%, and 75% of the expected number of primary endpoints, using events confirmed by the clinical events committee and respective efficacy conditional power futility boundaries of #10%, #15%, 
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A P R I L 2 0 1 6 : 1 8 0 -9 Detection and Management of Geographic Disparities in the TOPCAT and #20%. The trial reached completion, with 671 subjects having a primary event (8) . The hazard ratios (HR) and 95% confidence intervals (CI) for the primary endpoint was 0.89 (95% CI: 0.77 to 1.04), p ¼ 0.14 (8) and 0.83 (95% CI: 0.69 to 0.99), p ¼ 0.04 for time to HF hospitalization as a single endpoint (8) .
The TOPCAT protocol defined HFpEF as follows:
1) having at least 1 HF symptom present during screening; 2) 1 HF sign present during the last 12 months; and 3) meeting criteria for 1 of 2 design strata: at least 1 hospitalization in the last 12 months "for which heart failure had to be a major component Of the 981 patients enrolled by NP criteria, 81%
were from North or South America. Additional evidence of geographic differences in outcomes by country and region were noted (8, 11) . Patients enrolled in Russia and Georgia had lower event rates in the placebo arm, and in the spironolactone arm, they showed no evidence of hyperkalemia or renal dysfunction despite having an increased incidence of gynecomastia plus no evidence of a treatment effect (8, 11) . The HR of the primary endpoint for patients Figure 3 shows the dominance of Russia and Georgia in the early phases of trial enrollment, followed by the steady ascendancy of E m e r g e n c e a n d d e t e c t i o n ; t a c t i c a l r e s p o n s e s . These data were insufficient for drawing firm conclusions, but in response, the DSMB recommended that the trial leadership "encourage Georgian Investigators to enroll patients as expected per the study protocol."
Detection and Management of Geographic Disparities in the TOPCAT
At the September 2008 meeting, the DSMB approved a plan to reduce the total target enrollment from 4,500 to 3,515 patients with 2 years of minimum follow-up, based on the aggregate event rate being as expected and estimated length of median follow-up being longer, plus accepting a power calculation of >80% as opposed to 90%. In this event-driven trial, the new sample size calculations were based on 80% and 85% power for 551 and 630 primary events, respectively, assuming a 20% relative difference Sampling interval dates on the x-axis are either from the review data freeze or updated numbers available immediately prior to the DSMB review. Abbreviations as in Figure 1 .
Georgia was within the normal range (respectively, 233 pg/ml and 164 pg/ml), whereas it was markedly elevated (887 pg/ml) in the United States and Canadian patients. Concerns over these data were Nevertheless, the low (208 pg/ml combined) median values of Russian and Georgian patients were known to be associated with low mortality or cardiovascular hospitalization event rates in heart failure with reduced ejection fraction (13) and were subsequently shown to be associated with a low composite cardiovascular mortality and HF hospitalization rate in HFpEF (14) . Thus, although the NP data from the pilot study did not allow a direct comparison of Eastern European enrolled patients to those enrolled in the Americas, they were consistent with the low primary event rates in Russia and Georgia. After extensive discussion of this issue, it was decided to terminate the NP pilot study and to again emphasize to Russian and Georgian investigators to ensure that patients hospitalized for apparent HF met the eligibility criteria for the trial. The final interim analysis, at 75% of the projected number of primary events, was conducted at the June 2012 review (Figure 1 ). Conditional power again was well above the futility boundary (20%) and was 51% using the observed event rates in each arm modeled forward to the completion of follow-up, or 69% using the observed placebo event rate but the pre-trial/ expected 20% difference in crude event rates in the remaining patients active in the trial who had not had a primary event. The country-specific HR and number of events are shown in Table 2 . Based on 382 patients with confirmed primary events, the overall HR was 0.792 (p ¼ 0.020, efficacy boundary for stopping ¼ 0.001). At this interim, an additional 161 patients had unconfirmed events that were pending adjudication, and when they were included, the HR p value was 0.118. Country-specific HR were available for the first time and are shown in Table 2 . For the confirmed events, there was no evidence of a treatment effect in A predominance of ischemic heart disease symptoms, however, was apparently not the issue in patients enrolled in the Republic of Georgia, who from the beginning of the trial had a very low event rate and little evidence for HF based on signs and symptoms or random NP measurements. The lack of any treatment effect in these patients may well have been due to the fact that HF was either absent or much milder than in those enrolled in the Americas.
Although study drug compliance did not appear to account for the lack of treatment effect in Russia and Georgia, as these countries reported using higher doses of both spironolactone and placebo (11) , in the spironolactone arm, there was a substantially higher incidence of hyperkalemia and elevations in serum creatinine in the Americas than in Russia and Georgia (11) . This was interpreted as a "lack of pharmacologic effect" in Russian and Georgian patients (11) , but it could also be due to the absence of actual study drug consumption. However, Russian and Georgian patients had an increase in gynecomastia in the spironolactone versus the placebo arm (11), indicating they were likely taking study medication. Gynecomastia in the absence of marked hyperkalemia has been observed in another spironolactone versus placebo HFpEF study (16) and could be characteristic of a subcohort of patients. These pharmacodynamic adverse event data were not reviewed by country during the trial by the DSMB, although they were being tracked monthly for the entire trial. Countryspecific adverse events and severe adverse events within their standard regulatory organ system groupings were tracked by the DSMB, and no obvious differences between countries or regions were noted in any review.
LESSONS LEARNED AND RECOMMENDATIONS FOR FUTURE TRIALS
LESSONS LEARNED. Whereas the country-specific and regional heterogeneity in TOPCAT could be viewed as expected statistical variation in a large multinational trial (1,3), the differences in patient characteristics, lower event rates, lack of certain drug class-related pharmacodynamic effects (11), and complete lack of treatment effect in Russia and
Georgia compared with the other regions strongly suggest that more than the play of chance occurred.
E n r o l l m e n t i s s u e s . Because of the difficulty in identifying the phenotype (17) and other issues, enrollment of patients into HFpEF clinical trials can be challenging. Consequently, in HFpEF trials, the pressure to enroll at a projected rate versus the imperative to confine enrollment to the target population is even more in conflict than usual. TOPCAT started behind schedule, and once begun, there was brisk enrollment from 2 countries where data ultimately proved to be qualitatively problematic. By the time it was appreciated that there were serious issues with patient characteristics and event rates in patients from Russia and Georgia, both countries had enrolled substantial numbers of subjects. The lesson learned here is that during the early as well as the later phases of trial enrollment, recruitment from 1 or 2 regions or sites should not dominate, and patient characteristics should be monitored carefully to identify potential regional irregularities in study subpopulations.
W h a t y o u s e e e a r l y m a y b e w h a t y o u g e t l a t e . I n a l a r g e , m u l t i c e n t e r c l i n i c a l t r i a l , c h a n g e i s R e q u i r e m e n t o f a n e l e v a t e d B -t y p e n a t r i u r e t i c p e p t i d e m e a s u r e m e n t i n f u t u r e H F p E F t r i a l s ? As referenced in the trial overview section, the HR in the 981 patients enrolled with an elevated BNP or NT-proBNP was highly statistically significant at 0.65 compared with the nonsignificant HR in the 2,464
patients enrolled based on a history of HF hospitalization (8, 11) . In HFpEF an elevated NP level adds precision to the HF diagnosis and provides objective evidence for a certain degree of HF severity (13, 14) . analysis. Specifically, when a late/pre-specified interim analysis has a HR within certain boundaries termed the "promising zone" the sample size may be increased without inflating type 1 error (19, 20) . In general the promising zone band encompasses conditional powers between 50% and 80% (19, 20) , which is where the TOPCAT conditional power calculations were at the 75% interim. Operationally, the option to increase sample size by a pre-specified amount based on conditional power or Bayesian predictive probabilities needs to be prospectively defined, and the sponsor must be willing to support the increase in trial budget to account for the sample size increase. 
